HC Wainwright Issues Pessimistic Estimate for VNDA Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at HC Wainwright reduced their Q2 2025 EPS estimates for shares of Vanda Pharmaceuticals in a report issued on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of ($0.35) per share for the quarter, down from their previous estimate of ($0.19). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.38) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.01) EPS and FY2026 earnings at $0.03 EPS.

Other analysts have also issued reports about the stock. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA opened at $4.16 on Friday. The stock has a market capitalization of $245.17 million, a PE ratio of -13.00 and a beta of 0.69. Vanda Pharmaceuticals has a 1 year low of $3.81 and a 1 year high of $6.75. The company’s 50-day simple moving average is $4.44 and its 200-day simple moving average is $4.63.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The firm had revenue of $50.04 million during the quarter, compared to analyst estimates of $45.13 million.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock in a transaction dated Friday, February 28th. The shares were acquired at an average cost of $4.76 per share, with a total value of $47,600.00. Following the completion of the transaction, the chief executive officer now owns 2,361,730 shares in the company, valued at approximately $11,241,834.80. This trade represents a 0.43% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 32,000 shares of company stock worth $151,180 in the last 90 days. 10.00% of the stock is owned by company insiders.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its position in shares of Vanda Pharmaceuticals by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 3,370 shares during the last quarter. ProShare Advisors LLC grew its position in Vanda Pharmaceuticals by 32.4% in the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 4,599 shares in the last quarter. Brandywine Global Investment Management LLC grew its position in Vanda Pharmaceuticals by 13.9% in the 4th quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 4,820 shares in the last quarter. MetLife Investment Management LLC grew its position in Vanda Pharmaceuticals by 18.9% in the 1st quarter. MetLife Investment Management LLC now owns 32,816 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 5,210 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 5,459 shares in the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.